Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of hbv infection over up to nine years

被引：0
|
作者：
Van Boemmel, E.
Brodzinski, A.
Mihm, U.
Jung, M. C.
Sarrazin, C.
Bergk, A.
Schlosser, B.
Weich, V.
Schott, E.
Wiedenmann, B.
Berg, T.
机构：
[1] Univ Med Berlin, Charite, Med klin Mit Schwerpunkt Hepatol & Gastroenterol, Berlin, Germany
[2] Univ Klinikum Saarlandes, Klin & Polyklin Innere Med 2, Homburg, Germany
[3] Univ Munich, Klinikum Grosshadern, Med Klin 2, D-8000 Munich, Germany
来源：
JOURNAL OF HEPATOLOGY | 2007年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
521
引用
收藏
页码：S198 / S198
页数：1
相关论文
共 50 条
  • [1] Multifactorial analysis of host and virus related risk factors for the development of viral resistance during long-term lamivudine treatment of HBV infection.
    van Bömmel, F
    Mihm, U
    Jung, CM
    Sarrazin, C
    Gerlach, T
    Bergk, A
    Hopf, U
    Wiedenmann, B
    Berg, T
    HEPATOLOGY, 2003, 38 (04) : 720A - 721A
  • [2] Long-term treatment with lamivudine up to ten years:: Predictive value of host and virus related risk factors for the development of HBV resistance
    van Boemmel, F.
    Brodzinski, A.
    Mihm, U.
    Jung, M. C.
    Sarrazin, C.
    Bergk, A.
    Schlosser, B.
    Weichl, V.
    Mueller, T.
    Schott, E.
    Wiedenmann, B.
    Berg, T.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S264 - S265
  • [3] Long-term treatment with lamivudine up to ten years: Predictive value of host and virus related risk factors for the development of HBV resistance
    van Boemmel, Florian
    Brodzinski, Annika
    Mihm, Ulrike
    Jung, Maria-Christina
    Sarrazin, Christoph
    Bergk, Alexandra
    Schlosser, Beate
    Chauvel, Morgane
    Biermer, Michael
    Mueller, Tobias
    Schott, Eckart
    Wiedenmann, Bertram
    Berg, Thomas
    GASTROENTEROLOGY, 2008, 134 (04) : A50 - A50
  • [4] Long-term treatment with lamivudine (LMV) for up to 12 years: Predictive value of virus and host related risk factors for the development of HBV resistance
    Brodzinski, Annika
    Mihm, Ulrike
    Sarrazin, Christoph
    Jung, Maria-Christina
    Schott, Eckart
    Fueloep, Balazs
    Schlosser, Beate
    Biermer, Michael
    Boehm, Stephan
    Moessner, Joachim
    Berg, Thomas
    van Boemmel, Florian
    HEPATOLOGY, 2012, 56 : 398A - 398A
  • [5] No evidence for tenofovir resistance in patients with lamivudine-resistant HBV infection during long-term treatment for up to 5 years
    van Boemmel, Florian
    Mauss, Stefan
    Schuermann, Dirk
    Hueppe, Dietrich
    Neuhaus, Ruth
    Reinke, Petra
    Christoph, Sarrazin
    Spengler, Ulrich
    Moeller, Bernd
    Zoellner, Bernhard
    Wiedenmann, Bertram
    Berg, Thomas
    HEPATOLOGY, 2006, 44 (04) : 549A - 549A
  • [6] Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections
    Koukoulioti, Eleni
    Brodzinski, Annika
    Mihm, Ulrike
    Sarrazin, Christoph
    Jung, Maria-Christina
    Schott, Eckart
    Fueloep, Balazs
    Schlosser, Beate
    Berg, Thomas
    van Boemmel, Florian
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (07) : 845 - 852
  • [7] The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Akuta, N
    Suzuki, F
    Kobayashi, M
    Tsubota, A
    Suzuki, Y
    Hosaka, T
    Someya, T
    Kobayashi, M
    Saitoh, S
    Arase, Y
    Ikeda, K
    Kumada, H
    JOURNAL OF HEPATOLOGY, 2003, 38 (03) : 315 - 321
  • [8] Risk assessment for the development of hepatocellular carcinoma: According to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease
    Eun, Jong Ryul
    Lee, Heon Ju
    Kim, Tae Nyeun
    Lee, Kyeung Soo
    JOURNAL OF HEPATOLOGY, 2010, 53 (01) : 118 - 125
  • [9] Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    Suzuki, F
    Tsubota, A
    Akuta, N
    Someya, T
    Kobayashi, M
    Suzuki, Y
    Saitoh, S
    Arase, Y
    Ikeda, K
    Miyakawa, Y
    Kumada, H
    JOURNAL OF GASTROENTEROLOGY, 2002, 37 (11) : 922 - 927
  • [10] Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy
    Fumitaka Suzuki
    Akihito Tsubota
    Norio Akuta
    Takashi Someya
    Masahiro Kobayashi
    Yoshiyuki Suzuki
    Satoshi Saitoh
    Yasuji Arase
    Kenji Ikeda
    Yuzo Miyakawa
    Hiromitsu Kumada
    Journal of Gastroenterology, 2002, 37 : 922 - 927
12345